Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ

Journal of Pathology

Volumn 239, Issue 3, 2016, Pages 344-354

  Ramalingam, Thirumalai R ^a   Gieseck, Richard L ^a   Acciani, Thomas H ^a   M Hart, Kevin ^a   Cheever, Allen W ^a   Mentink Kane, Margaret M ^b   Vannella, Kevin M ^a   Wynn, Thomas A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

collagen; fibroblast; fibrosis; hydroxyproline; interferon; interleukin 13; liver; lung; tumour necrosis factor

Indexed keywords

COLLAGEN; GAMMA INTERFERON; HYDROXYPROLINE; INTERLEUKIN 13; MACROPHAGE ELASTASE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; INFLAMMATION; INTERFERON PRODUCTION; LIVER FIBROSIS; LUNG FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SIGNAL TRANSDUCTION;

EID: 84976286534     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4733     Document Type: Article

References (59)

1. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nature Rev Immunol 2015; 15: 271–282.
2. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nature Rev Immunol 2013; 13: 666–678.
3. Choy DF, Hart KM, Borthwick LA, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7: 301ra129.
4. Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature 2012; 484: 465–472.
5. Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nature Rev Immunol 2013; 13: 607–614.
6. Voehringer D. Protective and pathological roles of mast cells and basophils. Nature Rev Immunol 2013; 13: 362–375.
7. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells – how did we miss them? Nature Rev Immunol 2013; 13: 75–87.
8. McKenzie GJ, Fallon PG, Emson CL, et al. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999; 189: 1565–1572.
9. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258–2261.
10. Allen JE, Wynn TA. Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathogens 2011; 7: e1002003.
11. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature Med 2012; 18: 1028–1040.
12. O'Reilly S. Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors 2013; 39: 593–596.
13. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199–210.
14. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70: 748–756.
15. Scalori A, Belloni P, Ackrill A, et al. Lebrikizumab idiopathic pulmonary fiborsis trial: phase II randomized, double-blind, placebo controlled study to assess efficacy and safety (RIFF). Respirology 2014; 19: 145.
16. Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999; 104: 777–785.
17. Borthwick LA, Barron L, Hart KM, et al. Macrophages are critical to the maintenance of IL-13-dependent lung inflammation and fibrosis. Mucosal Immunol 2016; 9: 38–55.
18. Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000; 292: 988–994.
19. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791–808.
20. Chiaramonte MG, Schopf LR, Neben TY, et al. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999; 162: 920–930.
21. Fallon PG, Richardson EJ, McKenzie GJ, et al. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000; 164: 2585–2591.
22. Chiaramonte MG, Cheever AW, Malley JD, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 2001; 34: 273–282.
23. Wynn TA, Eltoum I, Oswald IP, et al. Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 1994; 179: 1551–1561.
24. Fairfax K, Nascimento M, Huang SC, et al. Th2 responses in schistosomiasis. Semin Immunopathol 2012; 34: 863–871.
25. Ghosh AK, Yuan W, Mori Y, et al. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001; 276: 11041–11048.
26. Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004; 173: 4020–4029.
27. Vaillant B, Chiaramonte MG, Cheever AW, et al. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001; 167: 7017–7026.
28. Madala SK, Pesce JT, Ramalingam TR, et al. Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 2010; 184: 3955–3963.
29. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 2000; 164: 6406–6416.
30. Sutherland TE, Logan N, Ruckerl D, et al. Chitinase-like proteins promote IL-17-mediated neutrophilia in a tradeoff between nematode killing and host damage. Nature Immunol 2014; 15: 1116–1125.
31. Jankovic D, Kullberg MC, Noben-Trauth N, et al. Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. J Immunol 1999; 163: 337–342.
32. Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453: 236–240.
33. Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 2003; 197: 687–701.
34. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088–1098.
35. Chandriani S, DePianto DJ, N'Diaye EN, et al. Endogenously expressed IL-13Ralpha2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol 2014; 193: 111–119.
36. Murray LA, Zhang H, Oak SR, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol 2014; 50: 985–994.
37. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994; 12: 635–673.
38. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991; 5: 171–177.
39. Lukacs NW, Hogaboam C, Chensue SW, et al. Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. Chest 2001; 120: 5S-8S.
40. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Rev Immunol 2004; 4: 583–594.
41. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 1997; 94: 10663–10668.
42. Wynn TA, Cheever AW, Jankovic D, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376: 594–596.
43. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125–133.
44. Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362: 248–250.
45. Doherty TM, Kastelein R, Menon S, et al. Modulation of murine macrophage function by IL-13. J Immunol 1993; 151: 7151–7160.
46. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442–452.
47. Kleinbongard P, Schulz R, Heusch G. TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev 2011; 16: 49–69.
48. Booth M, Mwatha JK, Joseph S, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 2004; 172: 1295–1303.
49. Mwatha JK, Kimani G, Kamau T, et al. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J Immunol 1998; 160: 1992–1999.
50. Dessein A, Kouriba B, Eboumbou C, et al. Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. Immunol Rev 2004; 201: 180–190.
51. Dessein AJ, Hillaire D, Elwali NE, et al. Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet 1999; 65: 709–721.
52. Henri S, Chevillard C, Mergani A, et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol 2002; 169: 929–936.
53. de Jesus AR, Magalhaes A, Miranda DG, et al. Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection. Infect Immun 2004; 72: 3391–3397.
54. Pearce EJ, Caspar P, Grzych JM, et al. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991; 173: 159–166.
55. Licona-Limon P, Kim LK, Palm NW, et al. TH2, allergy and group 2 innate lymphoid cells. Nature Immunol 2013; 14: 536–542.
56. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med 2012; 18: 716–725.
57. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nature Immunol 2001; 2: 816–822.
58. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693–699.
59. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998; 394: 909–913.